XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Nov. 15, 2021
Mar. 31, 2023
Feb. 28, 2023
Mar. 31, 2024
Mar. 31, 2023
Jan. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Settled liability         $ 365  
(Gain) loss on fair value remeasurement of deferred purchase consideration         (230)  
Contingent milestone consideration paid in shares value         2,354  
Loss (gain) on fair value remeasurement of contingent consideration       $ (158) $ (1,847)  
Change in fair value of deferred purchase consideration       0    
Combangio, Inc.            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Number of shares 155,664          
Combangio, Inc. | Shares Issued on January 3, 2022            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Number of shares 136,314          
Combangio, Inc. | Shares not issued until escrow release date of March 2023            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Number of shares 19,350          
Combangio, Inc. | First patient dosed with any product in phase 2 clinical trial, dosing milestone            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Contingent milestone consideration           $ 146
Contingent milestone consideration paid     $ 2,500 2,646    
Contingent milestone consideration paid in shares value     $ 2,354 $ 2,354    
Contingent milestone consideration paid in shares   105,038   105,038    
Combangio, Inc. | Maximum            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis            
Contingent milestone consideration $ 105,000